These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 21820930)
1. [Discontinuation and long-term adherence to beta interferon therapy in patients with multiple sclerosis]. Vicente Iturbe C; Ara Callizo JR; Huarte Lacunza R; Navarro Aznárez H; Serrano Mislata N; Rabanaque Hernández MJ Farm Hosp; 2012; 36(2):77-83. PubMed ID: 21820930 [TBL] [Abstract][Full Text] [Related]
2. Long-term adherence to interferon-beta treatment in a cohort of RRMS patients in Belgrade, Serbia. Mesaroš S; Stojsavljević N; Dujmović-Bašuroski I; Dejanović I; Pekmezović T; Drulović J Clin Neurol Neurosurg; 2012 Oct; 114(8):1145-8. PubMed ID: 22425462 [TBL] [Abstract][Full Text] [Related]
3. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study. Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960 [TBL] [Abstract][Full Text] [Related]
4. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta]. Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805 [TBL] [Abstract][Full Text] [Related]
5. [Long term effect of interferon-beta on disease severity in relapsing-remitting multiple sclerosis patients]. Patrucco L; Rojas JI; Cristiano E Rev Neurol; 2010 May; 50(9):529-32. PubMed ID: 20443171 [TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. Reynolds MW; Stephen R; Seaman C; Rajagopalan K J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189 [TBL] [Abstract][Full Text] [Related]
7. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis. Reynolds MW; Stephen R; Seaman C; Rajagopalan K Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144 [TBL] [Abstract][Full Text] [Related]
8. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466 [TBL] [Abstract][Full Text] [Related]
9. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM; Johnson BH; Wenten M; Watson C Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422 [TBL] [Abstract][Full Text] [Related]
10. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis. Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235 [TBL] [Abstract][Full Text] [Related]
11. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722 [TBL] [Abstract][Full Text] [Related]
12. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353 [TBL] [Abstract][Full Text] [Related]